NCT02535325 - Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 27, 2020

Study Completion Date

June 14, 2022

Conditions

Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Adenocarcinoma AJCC v7Stage III Lung Large Cell Carcinoma AJCC v7Stage III Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Adenocarcinoma AJCC v7Stage IIIA Lung Large Cell Carcinoma AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Adenocarcinoma AJCC v7Stage IIIB Lung Large Cell Carcinoma AJCC v7Stage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Lung Adenocarcinoma AJCC v7Stage IV Lung Large Cell Carcinoma AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

RADIATION

3-Dimensional Conformal Radiation Therapy

Undergo 3-D conformal RT

DRUG

Cisplatin

Given IV

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

DRUG

Methoxyamine

Given PO

DRUG

Methoxyamine Hydrochloride

Given PO

DRUG

Pemetrexed

Given IV

DRUG

Pemetrexed Disodium

Given IV

Trial Locations (1)

44106

Case Western Reserve University, Cleveland

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH